Search Results - "BULGER, T. F"

  • Showing 1 - 5 results of 5
Refine Results
  1. 1

    Administration of anaesthetic triggering agents to patients tested malignant hyperthermia normal and their relatives in New Zealand: An update by Frei, D., Stowell, K. M., Langton, E. E., McRedmond, L., Pollock, N. A., Bulger, T. F.

    Published in Anaesthesia and intensive care (01-09-2017)
    “…Testing for malignant hyperthermia in New Zealand involves two tests-in vitro contracture testing of excised lateral quadriceps muscle and DNA analysis. In…”
    Get full text
    Journal Article
  2. 2

    Preparation of Datex-Ohmeda Aestiva® and Aisys® anaesthetic machines for use in malignant hyperthermia susceptible patients by JONES, C, BENNETT, K, KIM, T. W, BULGER, T. F, POLLOCK, N

    Published in Anaesthesia and intensive care (01-05-2012)
    “…Preparation of anaesthesia machines for use by malignant hyperthermia susceptible patients requires purging the machines of halogenated anaesthetic agents. The…”
    Get full text
    Journal Article
  3. 3

    Safety of exposure of malignant hyperthermia non-susceptible patients and their relatives to anaesthetic triggering agents by POLLOCK, N, LANGTON, E. E, STOWELL, K. M, BULGER, T. F

    Published in Anaesthesia and intensive care (01-09-2011)
    “…As the reliability of malignant hyperthermia normal in vitro contracture test results has been questioned, this study set out to determine the reliability of…”
    Get full text
    Journal Article
  4. 4

    Evidence of Malignant Hyperthermia in Patients Administered Triggering Agents before Malignant Hyperthermia Susceptibility Identified: Missed Opportunities Prior to Diagnosis by Chan, T. Y., Bulger, T. F., Stowell, K. M., Gillies, R. L., Langton, E. E., Street, N. E., Pollock, N. A.

    Published in Anaesthesia and intensive care (01-11-2017)
    “…Malignant hyperthermia (MH) is a hypermetabolic disorder of skeletal muscle triggered almost exclusively by potent inhalational agents and suxamethonium. Signs…”
    Get full text
    Journal Article
  5. 5

    Evidence of malignant hyperthermia in patients administered triggering agents before malignant hyperthermia susceptibilityidentified: Missed opportunities prior to diagnosis by TY Chan, TF Bulger, KM Stowell, RL Gillies, EE Langton, NE Street, NA Pollock

    Published in Anaesthesia and intensive care (01-11-2017)
    “…Malignant hyperthermia (MH) is a hypermetabolic disorder of skeletal muscle triggered almost exclusively by potent inhalational agents and suxamethonium. Signs…”
    Get full text
    Journal Article